Dimopoulos: We are on constant alert to avoid lockdown
In the preparation, vigilance and compliance with individual protection measures to prevent the transmission of the coronavirus, SARS-CoV-2, in order to avoid the “red alert” and the difficult path of “lockdown” calls on everyone, addressing the APE-MPE, the rector of the EKPA Thanos Dimopoulos. It places particular emphasis on educating and informing citizens so that compliance with protective measures becomes a habit and a part of daily routine.
“The epidemiological picture of the COVID-19 infection in recent days in our country is of particular concern, especially in regions where there is a marked outbreak of cases, such as Attica. In order to avoid” the alert red “, without exception, we must all adapt our daily life to the new conditions and with a sense of individual and social responsibility to observe measures to prevent the transmission of the new coronavirus SARS-CoV-2”.
“Lockdown” is not an easy route
Regarding the possibility of leading to a new “lockdown”, Mr. Dimopoulos pointed out to the EPA-MPE that the “lockdown” is a horizontal measure with multiple socio-economic consequences in the short and long term. Therefore, it can be described as anything but an “easy road”.
Compliance with individual protection measures is a challenge, especially since it must be done over the long term. It is therefore clear that the real challenge is to educate citizens to make protection a habit and part of their daily life. Constant information of the public is necessary for the use of all means of communication and by all organizations, scientists, politicians, entertainment people. The education of the youngest, children and young adults, through school and university is crucial “.
Twenty-seven vaccines are being evaluated for their safety in humans in small phase 1 studies and Fourteen are in phase 2 studies with more volunteers and are being evaluated for efficacy and safety.
Eleven vaccines are currently being evaluated in large phase 3 studies which, if they show encouraging efficacy and safety results, will lead to regulatory approval.
“The first clear results regarding the safety and efficacy of vaccines against SARS-CoV-2 from the ongoing Phase 3 clinical trials are expected to be announced by January 2021, but it will take a few months for a widely available vaccine,” Dimopoulos said.